lanreotide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
peptides and glycopeptides	1546	108736-35-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lanreotide angiopeptin ipstyl lanreotide autogel somatulin-autogel somatuline lanreotide acetate	synthetic octapeptide analog of somatostatin; inhibits accelerated transplant atherosclerosis in rabbit heart arteries Molecular weight: 1096.33 Formula: C54H69N11O10S2 CLOGP: 3.42 LIPINSKI: 3 HAC: 21 HDO: 13 TPSA: 355.08 ALOGS: -5.34 ROTB: 17 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lanreotide
angiopeptin
ipstyl
lanreotide autogel
somatulin-autogel
somatuline
lanreotide acetate

synthetic octapeptide analog of somatostatin; inhibits accelerated transplant atherosclerosis in rabbit heart arteries

Molecular weight: 1096.33
Formula: C54H69N11O10S2
CLOGP: 3.42
LIPINSKI: 3
HAC: 21
HDO: 13
TPSA: 355.08
ALOGS: -5.34
ROTB: 17

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
3	mg	P

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	0.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.03 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 30, 2007	FDA	IPSEN PHARMA
Dec. 12, 2020	PMDA	TEIJIN PHARMA LIMITED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	267.59	18.94	178	9629	103787	63375428
Injection site mass	219.55	18.94	89	9718	18567	63460648
Insulin-like growth factor increased	208.64	18.94	44	9763	875	63478340
Diarrhoea	174.12	18.94	356	9451	715010	62764205
Injection site pain	137.46	18.94	132	9675	129668	63349547
Abdominal pain	104.87	18.94	173	9634	293283	63185932
Cholelithiasis	102.70	18.94	71	9736	43854	63435361
Flatulence	90.43	18.94	60	9747	34642	63444573
Abdominal distension	89.54	18.94	87	9720	86528	63392687
Blood growth hormone increased	86.87	18.94	19	9788	451	63478764
Neoplasm progression	76.14	18.94	55	9752	36373	63442842
Off label use	70.58	18.94	246	9561	674216	62804999
Carcinoid tumour pulmonary	64.80	18.94	15	9792	463	63478752
Disease progression	64.74	18.94	87	9720	122671	63356544
Injection site nodule	58.14	18.94	22	9785	3813	63475402
Intestinal obstruction	47.76	18.94	39	9768	30860	63448355
Terminal state	45.41	18.94	16	9791	2266	63476949
Carcinoid crisis	44.99	18.94	10	9797	256	63478959
Needle issue	42.58	18.94	24	9783	10352	63468863
Blood glucose increased	40.56	18.94	57	9750	83699	63395516
Menopausal symptoms	40.52	18.94	15	9792	2446	63476769
Carcinoid syndrome	39.92	18.94	8	9799	122	63479093
Bronchiolitis	38.92	18.94	15	9792	2732	63476483
Weight decreased	38.86	18.94	112	9695	276686	63202529
Abdominal pain upper	38.62	18.94	93	9714	206351	63272864
Hypoglycaemia	38.61	18.94	47	9760	60018	63419197
Nausea	37.32	18.94	242	9565	854229	62624986
Product dose omission issue	37.01	18.94	99	9708	234214	63245001
Asthenia	36.55	18.94	136	9671	383468	63095747
Blood glucose decreased	35.68	18.94	28	9779	20924	63458291
Steatorrhoea	33.92	18.94	9	9798	490	63478725
Flushing	33.28	18.94	49	9758	75038	63404177
Death	32.59	18.94	129	9678	374252	63104963
Insulin-like growth factor abnormal	31.25	18.94	5	9802	18	63479197
Incorrect route of product administration	31.03	18.94	29	9778	27423	63451792
Insulinoma	30.62	18.94	6	9801	81	63479134
Faeces pale	30.25	18.94	11	9796	1706	63477509
Injection site pruritus	30.13	18.94	36	9771	45080	63434135
Hepatic neoplasm	28.96	18.94	11	9796	1925	63477290
Rheumatoid arthritis	28.56	18.94	3	9804	253816	63225399
Blood chromogranin A increased	28.29	18.94	7	9800	288	63478927
Constipation	27.74	18.94	87	9720	224856	63254359
Drug hypersensitivity	27.60	18.94	7	9800	310680	63168535
Malaise	27.53	18.94	132	9675	415822	63063393
Malignant neoplasm progression	27.30	18.94	47	9760	82074	63397141
Product administered at inappropriate site	26.96	18.94	12	9795	3137	63476078
Decreased appetite	26.40	18.94	92	9715	250960	63228255
Vomiting	25.86	18.94	161	9646	559456	62919759
Arthropathy	25.85	18.94	3	9804	234789	63244426
Toxicity to various agents	25.23	18.94	4	9803	247246	63231969
Pituitary tumour removal	24.87	18.94	4	9803	15	63479200
Metastases to liver	24.86	18.94	24	9783	23615	63455600
Injection site haemorrhage	24.29	18.94	24	9783	24290	63454925
Rash	23.94	18.94	31	9776	560840	62918375
Gastroenteropancreatic neuroendocrine tumour disease	22.43	18.94	4	9803	31	63479184
Postoperative adhesion	21.89	18.94	6	9801	370	63478845
Muscle neoplasm	21.80	18.94	4	9803	37	63479178
Gallbladder neoplasm	21.61	18.94	4	9803	39	63479176
Lymphatic system neoplasm	21.26	18.94	4	9803	43	63479172
Thyroid neoplasm	21.25	18.94	11	9796	4008	63475207
Biliary dilatation	20.57	18.94	9	9798	2260	63476955
Injection site hypoaesthesia	20.23	18.94	6	9801	491	63478724
Hypersensitivity	20.19	18.94	10	9797	292675	63186540
Hospitalisation	19.98	18.94	42	9765	85039	63394176
Neoplasm	19.85	18.94	13	9794	7332	63471883
Body height increased	19.55	18.94	4	9803	68	63479147
Spleen disorder	19.50	18.94	7	9800	1046	63478169
Gastrointestinal hypomotility	19.32	18.94	7	9800	1074	63478141
Drug intolerance	19.19	18.94	12	9795	308649	63170566

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	191.42	23.30	126	6148	62170	34888487
Diarrhoea	167.80	23.30	270	6004	389642	34561015
Injection site pain	152.55	23.30	92	6182	38913	34911744
Insulin-like growth factor increased	132.20	23.30	33	6241	1210	34949447
Neoplasm progression	131.77	23.30	70	6204	23230	34927427
Injection site mass	98.42	23.30	39	6235	6587	34944070
Abdominal pain	87.63	23.30	126	6148	163492	34787165
Off label use	87.46	23.30	215	6059	419309	34531348
Disease progression	87.25	23.30	102	6172	107975	34842682
Flatulence	82.77	23.30	50	6224	21148	34929509
Injection site haemorrhage	71.63	23.30	35	6239	9733	34940924
Cholelithiasis	70.21	23.30	45	6229	21103	34929554
Carcinoid heart disease	67.94	23.30	10	6264	13	34950644
Pituitary tumour benign	48.94	23.30	14	6260	867	34949790
Incorrect route of product administration	47.80	23.30	31	6243	14814	34935843
Growth hormone deficiency	47.80	23.30	11	6263	283	34950374
Carcinoid crisis	38.59	23.30	9	6265	246	34950411
Pituitary tumour removal	38.13	23.30	5	6269	0	34950657
Death	37.85	23.30	156	6118	397893	34552764
Metastases to liver	35.54	23.30	25	6249	13638	34937019
Pancreatic neuroendocrine tumour metastatic	34.65	23.30	7	6267	95	34950562
Injection site nodule	32.50	23.30	12	6262	1671	34948986
Abdominal pain upper	32.33	23.30	51	6223	71439	34879218
Injection site abscess	32	23.30	10	6264	839	34949818
Terminal state	31.56	23.30	15	6259	3919	34946738
Insulin-like growth factor abnormal	31.46	23.30	5	6269	14	34950643
Steatorrhoea	29.05	23.30	9	6265	734	34949923
Product dose omission issue	27.49	23.30	64	6210	119647	34831010
Hepatic neoplasm	27.14	23.30	11	6263	1966	34948691
Hepatic pain	26.64	23.30	10	6264	1458	34949199
Acromegaly	26.43	23.30	5	6269	47	34950610
Asthenia	25.50	23.30	99	6175	245152	34705505
Abdominal distension	25.43	23.30	41	6233	58451	34892206
Drug interaction	25.19	23.30	5	6269	225941	34724716
Flushing	25.07	23.30	30	6244	32390	34918267
Abdominal discomfort	24.74	23.30	41	6233	59794	34890863
Malignant neoplasm progression	24.66	23.30	51	6223	87995	34862662
Bile duct stone	24.33	23.30	11	6263	2566	34948091

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	285.18	19.07	213	13530	133415	79597230
Diarrhoea	257.35	19.07	504	13239	879985	78850660
Insulin-like growth factor increased	243.14	19.07	58	13685	1828	79728817
Injection site pain	208.17	19.07	175	13568	129663	79600982
Injection site mass	196.81	19.07	87	13656	20097	79710548
Abdominal pain	174.40	19.07	270	13473	389299	79341346
Flatulence	163.34	19.07	98	13645	42626	79688019
Neoplasm progression	158.37	19.07	103	13640	51579	79679066
Cholelithiasis	132.74	19.07	93	13650	52571	79678074
Off label use	102.41	19.07	365	13378	906850	78823795
Abdominal distension	100.16	19.07	113	13630	119537	79611108
Disease progression	96.86	19.07	138	13605	184224	79546421
Injection site nodule	66.86	19.07	25	13718	3755	79726890
Carcinoid tumour pulmonary	66.43	19.07	15	13728	369	79730276
Intestinal obstruction	62.72	19.07	55	13688	42965	79687680
Insulin-like growth factor abnormal	61.41	19.07	10	13733	36	79730609
Terminal state	60.62	19.07	25	13718	4864	79725781
Toxicity to various agents	60.26	19.07	3	13740	421537	79309108
Asthenia	59.20	19.07	208	13535	511481	79219164
Injection site haemorrhage	58.32	19.07	44	13699	27826	79702819
Carcinoid heart disease	57.51	19.07	10	13733	58	79730587
Weight decreased	57.25	19.07	162	13581	355036	79375609
Carcinoid crisis	56.74	19.07	14	13729	509	79730136
Blood growth hormone increased	56.73	19.07	15	13728	721	79729924
Metastases to liver	55.51	19.07	43	13700	28271	79702374
Abdominal pain upper	52.74	19.07	118	13625	223701	79506944
Malignant neoplasm progression	52.02	19.07	88	13655	135902	79594743
Pituitary tumour removal	51.60	19.07	8	13735	19	79730626
Product dose omission issue	50.14	19.07	123	13620	247414	79483231
Flushing	49.14	19.07	68	13675	88200	79642445
Pituitary tumour benign	49.10	19.07	18	13725	2558	79728087
Growth hormone deficiency	49.10	19.07	12	13731	419	79730226
Steatorrhoea	48.88	19.07	14	13729	907	79729738
Nausea	48.77	19.07	306	13437	956890	78773755
Incorrect route of product administration	47.62	19.07	43	13700	34886	79695759
Hepatic neoplasm	47.56	19.07	19	13724	3407	79727238
Blood glucose increased	46.10	19.07	76	13667	114899	79615746
Injection site abscess	44.87	19.07	15	13728	1625	79729020
Death	44.38	19.07	204	13539	566310	79164335
Blood chromogranin A increased	42.39	19.07	11	13732	491	79730154
Menopausal symptoms	42.22	19.07	15	13728	1948	79728697
Needle issue	39.88	19.07	26	13717	13042	79717603
Vomiting	39.68	19.07	222	13521	665606	79065039
Insulinoma	38.93	19.07	8	13735	124	79730521
Drug hypersensitivity	37.38	19.07	4	13739	298912	79431733
Blood glucose decreased	37.15	19.07	33	13710	26201	79704444
Drug interaction	36.51	19.07	13	13730	415170	79315475
Faeces pale	36.28	19.07	15	13728	2935	79727710
Hypoglycaemia	35.25	19.07	63	13680	101531	79629114
Carcinoid syndrome	35.23	19.07	8	13735	202	79730443
Hepatic pain	34.74	19.07	16	13727	4056	79726589
Acromegaly	34.40	19.07	7	13736	103	79730542
Constipation	32.57	19.07	115	13628	282935	79447710
Rash	31.48	19.07	32	13711	578326	79152319
Bronchiolitis	31.24	19.07	15	13728	4173	79726472
Metastases to bone	29.29	19.07	28	13715	24399	79706246
Pituitary tumour	28.82	19.07	10	13733	1212	79729433
Bile duct stone	27.15	19.07	15	13728	5574	79725071
Biliary obstruction	26.79	19.07	14	13729	4660	79725985
Pneumonia	26.29	19.07	46	13697	660200	79070445
Decreased appetite	25.76	19.07	122	13621	342296	79388349
Injection site pruritus	25.68	19.07	34	13709	42249	79688396
Malaise	25.65	19.07	158	13585	489711	79240934
Thyroid neoplasm	25.65	19.07	12	13731	3152	79727493
Neoplasm	25.07	19.07	17	13726	9099	79721546
Tumour necrosis	24.41	19.07	10	13733	1912	79728733
Injection site induration	23.92	19.07	17	13726	9802	79720843
Gallbladder neoplasm	23.84	19.07	5	13738	86	79730559
Injection site hypoaesthesia	23.29	19.07	7	13736	537	79730108
Palliative care	23.08	19.07	8	13735	967	79729678
Hepatic embolisation	22.89	19.07	4	13739	24	79730621
Injection site discomfort	22.75	19.07	13	13730	5153	79725492
Acute kidney injury	22.71	19.07	34	13709	519370	79211275
Febrile neutropenia	22.50	19.07	6	13737	230993	79499652
Headache	21.13	19.07	188	13555	653584	79077061
Hepatobiliary disease	20.79	19.07	7	13736	775	79729870
Gastroenteropancreatic neuroendocrine tumour disease	20.73	19.07	4	13739	44	79730601
Hormone level abnormal	20.70	19.07	9	13734	1993	79728652
Arthropathy	20.59	19.07	3	13740	177108	79553537
Fatigue	20.41	19.07	247	13496	929480	78801165
Injection site scar	20.35	19.07	7	13736	826	79729819
Biliary colic	20.26	19.07	11	13732	3951	79726694
Muscle neoplasm	19.91	19.07	4	13739	55	79730590
Postoperative adhesion	19.86	19.07	6	13737	468	79730177
Lymphatic system neoplasm	19.52	19.07	4	13739	61	79730584
Dizziness	19.44	19.07	156	13587	526285	79204360
Keratitis	19.37	19.07	11	13732	4311	79726334
Sinusitis	19.18	19.07	5	13738	195496	79535149
Diabetes mellitus	19.18	19.07	42	13701	78348	79652297

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H01CB03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Somatostatin and analogues
FDA MoA	N0000000194	Somatostatin Receptor Agonists
MeSH PA	D000970	Antineoplastic Agents
FDA EPC	N0000175904	Somatostatin Analog

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acromegaly	indication	74107003	DOID:2449
Hypersomatotropic gigantism	indication	86073008
Thyroid-stimulating hormone secreting pituitary tumour	indication	127024001	DOID:1785
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Bradycardia	contraindication	48867003
Hyperglycemia	contraindication	80394007	DOID:4195
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Calculus in biliary tract	contraindication	266474003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.65	acidic
pKa2	12.16	acidic
pKa3	12.71	acidic
pKa4	13.18	acidic
pKa5	13.43	acidic
pKa6	13.67	acidic
pKa7	10.31	Basic
pKa8	6.97	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	SOMATULINE DEPOT	IPSEN PHARMA	N022074	Aug. 30, 2007	RX	SOLUTION	SUBCUTANEOUS	Sept. 15, 2024	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	SOMATULINE DEPOT	IPSEN PHARMA	N022074	Aug. 30, 2007	RX	SOLUTION	SUBCUTANEOUS	Sept. 15, 2024	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	SOMATULINE DEPOT	IPSEN PHARMA	N022074	Aug. 30, 2007	RX	SOLUTION	SUBCUTANEOUS	Sept. 15, 2024	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Somatostatin receptor type 5	GPCR	P35346	SSR5_HUMAN	AGONIST	Ki	9.30	IUPHAR	CHEMBL
Somatostatin receptor type 2	GPCR	P30874	SSR2_HUMAN	AGONIST	Ki	9.60	IUPHAR	CHEMBL
Somatostatin receptor type 4	GPCR	P31391	SSR4_HUMAN		Ki	7.18	PDSP
Somatostatin receptor type 1	GPCR	P30872	SSR1_HUMAN		Ki	6.30	PDSP
Somatostatin receptor type 3	GPCR	P32745	SSR3_HUMAN	AGONIST	Ki	8	IUPHAR
Somatostatin receptor type 2	GPCR		SSR2_MOUSE	AGONIST	Ki	9.10	IUPHAR
Somatostatin receptor type 3	GPCR		SSR3_MOUSE	AGONIST	IC50	8.20	IUPHAR
Somatostatin receptor type 5	GPCR		SSR5_RAT	AGONIST	Ki	7.60	IUPHAR
Somatostatin receptor type 2	GPCR		SSR2_RAT	AGONIST	Ki	8.80	IUPHAR
Somatostatin receptor type 3	GPCR		SSR3_RAT	AGONIST	Ki	6.90	IUPHAR

External reference:

ID	Source
4026631	VUID
N0000179366	NUI
D04666	KEGG_DRUG
127984-74-1	SECONDARY_CAS_RN
4026631	VANDF
C0209211	UMLSCUI
CHEBI:135901	CHEBI
CHEMBL1201185	ChEMBL_ID
CHEMBL1201184	ChEMBL_ID
DB06791	DRUGBANK_ID
C060347	MESH_SUPPLEMENTAL_RECORD_UI
2031	IUPHAR_LIGAND_ID
6649	INN_ID
0G3DE8943Y	UNII
71349	PUBCHEM_CID
236167	RXNORM
18121	MMSL
354365	MMSL
d04961	MMSL
005272	NDDF
005273	NDDF
327379003	SNOMEDCT_US
395765000	SNOMEDCT_US
429611006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1060	INJECTION	60 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1060	INJECTION	60 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1060	INJECTION	60 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1090	INJECTION	90 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1090	INJECTION	90 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1090	INJECTION	90 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1120	INJECTION	120 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1120	INJECTION	120 mg	SUBCUTANEOUS	NDA	29 sections
SOMATULINE DEPOT	HUMAN PRESCRIPTION DRUG LABEL	1	15054-1120	INJECTION	120 mg	SUBCUTANEOUS	NDA	29 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-870	INJECTION	120 mg	SUBCUTANEOUS	NDA	26 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-870	INJECTION	120 mg	SUBCUTANEOUS	NDA	26 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-880	INJECTION	60 mg	SUBCUTANEOUS	NDA	26 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-880	INJECTION	60 mg	SUBCUTANEOUS	NDA	26 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-890	INJECTION	90 mg	SUBCUTANEOUS	NDA	26 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-890	INJECTION	90 mg	SUBCUTANEOUS	NDA	26 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	76282-709	INJECTION	60 mg	SUBCUTANEOUS	NDA	27 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	76282-710	INJECTION	90 mg	SUBCUTANEOUS	NDA	27 sections
Lanreotide Acetate	HUMAN PRESCRIPTION DRUG LABEL	1	76282-711	INJECTION	120 mg	SUBCUTANEOUS	NDA	27 sections